Novartis AG/€NOVN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis AG
Novartis AG is a global healthcare company based in Switzerland, specializing in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's core business is centered around patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis operates in over 150 countries worldwide. Its strategic positioning is reinforced by significant investments in research and development, supporting a robust pipeline of innovative therapies. The company is headquartered in Basel, Switzerland, and emphasizes its competitive strength through advanced research capabilities and a diverse product portfolio.
Ticker
€NOVN
Sector
Primary listing
XGAT
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis AG Metrics
BasicAdvanced
€218B
19.04
€5.89
0.56
€3.65
3.25%
Price and volume
Market cap
€218B
Beta
0.56
52-week high
€114.60
52-week low
€86.43
Average daily volume
5.8K
Dividend rate
€3.65
Financial strength
Current ratio
0.818
Quick ratio
0.502
Long term debt to equity
57.222
Total debt to equity
77.607
Dividend payout ratio (TTM)
57.26%
Interest coverage (TTM)
17.47%
Profitability
EBITDA (TTM)
20,255.662
Gross margin (TTM)
76.28%
Net profit margin (TTM)
24.74%
Operating margin (TTM)
34.76%
Effective tax rate (TTM)
12.62%
Revenue per employee (TTM)
€627,820
Management effectiveness
Return on assets (TTM)
11.88%
Return on equity (TTM)
32.49%
Valuation
Price to earnings (TTM)
19.039
Price to revenue (TTM)
4.675
Price to book
4.8
Price to tangible book (TTM)
-15.73
Price to free cash flow (TTM)
15.297
Free cash flow yield (TTM)
6.54%
Free cash flow per share (TTM)
7.332
Dividend yield (TTM)
3.25%
Forward dividend yield
3.25%
Growth
Revenue change (TTM)
12.95%
Earnings per share change (TTM)
-12.59%
3-year revenue growth (CAGR)
4.33%
10-year revenue growth (CAGR)
0.70%
3-year earnings per share growth (CAGR)
-12.58%
10-year earnings per share growth (CAGR)
-1.49%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
Bulls say / Bears say
Novartis raised its full-year 2025 operating income guidance to low double-digit growth after adjusted Q1 net income jumped 22% to $4.48 billion, well above analyst projections (Reuters)
Revenue from breast cancer drug Kisqali surged 52% to $956 million and cholesterol therapy Leqvio rose 70% to $257 million in Q1, underscoring strong commercial momentum for key growth drivers (Reuters)
The FDA approved Rhapsido (remibrutinib) for chronic spontaneous urticaria on September 30, introducing a high-priced oral BTK inhibitor that delivered complete symptom relief in one-third of trial patients by week 12 (Reuters)
A U.S. federal judge denied Novartis’ request for a preliminary injunction to block MSN Pharmaceuticals from marketing a generic version of Entresto, ending its market exclusivity on July 16, 2025 and threatening to erode revenues from the $7.8 billion drug (Reuters)
Novartis’ Cosentyx failed to achieve sustained remission in a late-stage Phase III trial for giant cell arteritis, representing a setback in its immunology pipeline and raising questions about growth prospects in that therapeutic area (Reuters)
The proposed 100% U.S. tariff on imported patented pharmaceuticals poses policy risk and cost uncertainty for Novartis despite its planned $23 billion U.S. investment, as details of potential exemptions remain unclear (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis AG stock?
Novartis AG (NOVN) has a market cap of €218B as of October 26, 2025.
What is the P/E ratio for Novartis AG stock?
The price to earnings (P/E) ratio for Novartis AG (NOVN) stock is 19.04 as of October 26, 2025.
Does Novartis AG stock pay dividends?
Yes, the Novartis AG (NOVN) stock pays dividends to shareholders. As of October 26, 2025, the dividend rate is €3.6508 and the yield is 3.25%. Novartis AG has a payout ratio of 57.26% on a trailing twelve-month basis.
When is the next Novartis AG dividend payment date?
The next Novartis AG (NOVN) dividend payment date is unconfirmed.
What is the beta indicator for Novartis AG?
Novartis AG (NOVN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.